StockNews.com Begins Coverage on Accelerate Diagnostics (NASDAQ:AXDX)

StockNews.com began coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a research note issued to investors on Friday. The brokerage issued a hold rating on the medical research company’s stock.

Separately, BTIG Research upgraded shares of Accelerate Diagnostics to a “strong-buy” rating in a research report on Wednesday, December 11th.

Accelerate Diagnostics Trading Down 0.9 %

AXDX stock opened at $1.10 on Friday. The stock’s 50 day simple moving average is $1.62 and its 200 day simple moving average is $1.54. Accelerate Diagnostics has a 12-month low of $0.73 and a 12-month high of $4.28. The firm has a market cap of $27.55 million, a P/E ratio of -0.38 and a beta of 0.56.

Insider Activity at Accelerate Diagnostics

In other Accelerate Diagnostics news, Director John Patience bought 200,000 shares of the stock in a transaction on Tuesday, December 3rd. The shares were bought at an average price of $1.57 per share, with a total value of $314,000.00. Following the purchase, the director now directly owns 653,224 shares in the company, valued at $1,025,561.68. The trade was a 44.13 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 43.60% of the stock is owned by insiders.

Institutional Trading of Accelerate Diagnostics

An institutional investor recently bought a new position in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd bought a new stake in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned 0.08% of Accelerate Diagnostics as of its most recent SEC filing. Institutional investors and hedge funds own 17.14% of the company’s stock.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.